Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study ( NCT01712789; EudraCT number: 2012-001888-78). Clinical responses were observed at all CRBN expression levels. A trend in progression-free survival (PFS; p = .038) and a potential trend in overall survival (OS; p = .059) favoring high CRBN expressers were observed; however, no notable difference in overall response rate (ORR) was observed. ORR (30%), median PFS (17.7 weeks), and median OS (52.3 weeks) in low-CRBN expressers were comparable to those in the STRATUS intent-to-treat population (ORR, 33%; median PFS, 20.0 weeks; median OS, 51.7 weeks). A trend in ORR (p = .050) favoring higher cMYC expressers was observed with no notable difference in PFS or OS. This analysis does not support exploring CRBN as a biomarker for selecting patients for pomalidomide therapy.

Original publication




Journal article


Leuk lymphoma

Publication Date





462 - 470


Multiple myeloma, biomarker, cereblon, immunomodulatory agent, pomalidomide, Adaptor Proteins, Signal Transducing, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Computational Biology, Drug Resistance, Neoplasm, Female, Gene Expression, Gene Expression Profiling, Humans, Immunologic Factors, Male, Middle Aged, Molecular Sequence Annotation, Multiple Myeloma, Neoplasm Staging, Prognosis, Recurrence, Retreatment, Thalidomide, Treatment Outcome, Ubiquitin-Protein Ligases